Zenas BioPharma (NASDAQ:ZBIO) Rating Lowered to “Strong Sell” at Zacks Research

Zenas BioPharma (NASDAQ:ZBIO) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Tuesday,Zacks.com reports.

ZBIO has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $44.00 price objective on shares of Zenas BioPharma in a report on Tuesday. Wall Street Zen raised shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Guggenheim boosted their price target on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday. Finally, Jefferies Financial Group reissued a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a research report on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $44.14.

Zenas BioPharma Stock Down 1.9%

ZBIO opened at $23.03 on Tuesday. The stock has a fifty day moving average of $22.91 and a 200-day moving average of $27.15. The company has a market capitalization of $1.32 billion, a P/E ratio of -2.95 and a beta of -1.94. Zenas BioPharma has a fifty-two week low of $6.11 and a fifty-two week high of $44.60. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.66 and a current ratio of 5.61.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Monday, March 16th. The company reported ($4.54) EPS for the quarter, missing the consensus estimate of ($1.22) by ($3.32).

Insiders Place Their Bets

In other news, Director Patricia L. Allen bought 4,160 shares of the company’s stock in a transaction dated Friday, February 13th. The stock was bought at an average cost of $26.36 per share, for a total transaction of $109,657.60. Following the transaction, the director owned 19,860 shares of the company’s stock, valued at $523,509.60. This represents a 26.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Hongbo Lu purchased 25,985 shares of the business’s stock in a transaction dated Wednesday, February 11th. The shares were purchased at an average cost of $22.50 per share, with a total value of $584,662.50. Following the acquisition, the director owned 347,968 shares in the company, valued at $7,829,280. This trade represents a 8.07% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 202,845 shares of company stock worth $3,747,185 over the last ninety days. Corporate insiders own 16.50% of the company’s stock.

Institutional Trading of Zenas BioPharma

Several large investors have recently made changes to their positions in ZBIO. Quarry LP increased its stake in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares during the last quarter. Deutsche Bank AG lifted its stake in Zenas BioPharma by 4.5% during the fourth quarter. Deutsche Bank AG now owns 12,781 shares of the company’s stock worth $464,000 after purchasing an additional 554 shares during the last quarter. CWM LLC lifted its stake in Zenas BioPharma by 48.3% during the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after purchasing an additional 709 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Zenas BioPharma by 3.9% in the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock valued at $452,000 after purchasing an additional 765 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Zenas BioPharma by 5.8% in the 3rd quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock valued at $329,000 after purchasing an additional 818 shares in the last quarter.

Trending Headlines about Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company says funding supports continued development of obexelimab — a key clinical program that underpins long‑term value, which helps stabilize investor confidence. Zenas BioPharma Funding Supports Obexelimab Plans
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and kept a $44 price target, signaling strong upside from some sell‑side analysts and supporting bullish expectations. HC Wainwright Rating
• Neutral Sentiment: Citigroup trimmed its price target from $43 to $41 but maintained a “buy” rating — a modest downgrade to upside assumptions but not a change in overall endorsement. Citigroup Price Target Cut
• Neutral Sentiment: Morgan Stanley raised its target to $21 and kept an “equal weight”/Hold stance, reflecting a balanced near‑term view that recognizes pipeline potential but flags commercial and leverage uncertainties. Morgan Stanley / TipRanks Note
• Negative Sentiment: Quarterly results missed materially — Zenas reported EPS of ($4.54) vs. consensus of ($1.22). The magnitude of the miss increases short‑term downside risk and raises questions about near‑term cash burn and execution. Quarterly Earnings Press Release
• Negative Sentiment: New disclosure of an IPO‑related securities class action introduces additional financial and operational risk, which can pressure the stock while litigation remains unresolved. IPO-Related Class Action

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.